

The Companies Announcements Office,
The Australian Stock Exchange Limited
SYDNEY

Via: asxonline

ASX code: VRI

25th January 2005

LICENSING AGREEMENT WITH LARGEST DISTRIBUTOR IN ASIA.

VRI has completed a licensing agreement with Nuvanta Pte Ltd of Singapore for the marketing and distribution of VRI's proTract® products throughout Southeast Asia.

Nuvanta is a subsidiary of Zuellig Investments, and is described by CEO - Dr Daniel Zuellig - as being "specialized in the marketing of evidence-based nutraceuticals in cooperation with Zuellig Pharma, the distribution arm of the Interpharma Group" (ref: www.zuelligpharma.com).

With a turnover of more than US\$ 3 billion, Interpharma is the leading provider of distribution and manufacturing services for the healthcare industry in Asia.

VRI retains ownership of the proTract® brand and product registration in each country. Nuvanta will bear marketing costs and pay VRI a royalty on sales. VRI will also earn a margin on the provision of finished goods.

Executive Chairman Mr Kim Slatyer said the agreement with Zuellig is an important milestone for VRI. "As Australia represents only 1.5% of the global market for our products, our revenue generating potential is vastly increased as we secure product distribution in other regions. Furthermore, VRI's ability to partner with major companies in those regions is a great validation of our technology".

VRI is discussing licensing terms for proTract® with companies in China and India, and is in the process of identifying prospective partners in other regions.

For Further information contact:

Mr Kim Slatyer

+612 9209 4268

kim.slatyer@vribiomedical.com

www.vribiomedical.com

VRI BioMedical Ltd
is bringing science to wellness by
commercialising a range of
products for health maintenance and
disease prevention, based on robust
scientific and clinical research.
VRI BioMedical has developed
extensive intellectual property
in three platform technologies:
probiotics diagnostics vaccines

VRI BioMedical Ltd
ACN 084 464 193 ABN 97 084 464 193
Suite G09, 1 Central Avenue, Australian Technology Park, Eveleigh, Sydney NSW 1430, Australia
Phone: +61 2 9209 4268 Fax: +61 2 9209 4256